Form 4: Director Hongbo Lu Sells Arrowhead Pharmaceuticals Stock

Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals common stock at $76.88 per share.

Summary

• Director Hongbo Lu executed a sale of 2,970 shares of Arrowhead Pharmaceuticals (ARWR) common stock.
• The transaction occurred on May 12, 2026, at a price of $76.88 per share.
• Following the sale, the reporting person retains beneficial ownership of 52,012 shares.
• The sale was conducted pursuant to a pre-established Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-arranged 10b5-1 plan, which is a routine mechanism for insider stock liquidation.

Positives

• The transaction was executed under a pre-planned Rule 10b5-1 trading plan, which typically indicates the sale was scheduled in advance for personal financial planning rather than based on non-public information.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the current valuation of the company.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The sale was conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for corporate executives and directors to manage personal liquidity and is generally viewed as neutral by institutional investors when pre-planned.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to avoid potential conflicts of interest regarding insider trading regulations.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the director's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Insider Trading, Form 4, Biotech, Director Sale